Immunology in the liver-from homeostasis to disease

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 2, 2016, Pages 88-110

  Heymann, Felix ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; COMPLEMENT; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 33; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ACUTE HEPATITIS; ACUTE LIVER FAILURE; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; CYTOKINE RELEASE; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; LIVER; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MACROPHAGE; MONOCYTE; MUCOSAL ASSOCIATED INVARIANT T LYMPHOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS HEPATITIS; ADAPTIVE IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; LIVER DISEASE; PHYSIOLOGY;

ADAPTIVE IMMUNITY; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; LIVER; LIVER DISEASES;

EID: 84956782591     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.200     Document Type: Review

References (248)

1. Bottcher, J. P., Knolle, P. A. & Stabenow, D. Mechanisms balancing tolerance and immunity in the liver. Dig. Dis. 29, 384-390 (2011).
2. Racanelli, V. & Rehermann, B. The liver as an immunological organ. Hepatology 43, S54-S62 (2006).
3. Orlando, G., Soker, S. & Wood, K. Operational tolerance after liver transplantation. J. Hepatol. 50, 1247-1257 (2009).
4. Knolle, P. A. & Thimme, R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146, 1193-1207 (2014).
5. Crispe, I. N. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147-163 (2009).
6. Matsumura, T., Ito, A., Takii, T., Hayashi, H. & Onozaki, K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J. Interferon Cytokine Res. 20, 915-921 (2000).
7. Seki, E. et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007).
8. Thomson, A. W. & Knolle, P. A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10, 753-766 (2010).
9. Brunt, E. M. et al. Pathology of the liver sinusoids. Histopathology 64, 907-920 (2014).
10. Zimmermann, H. W., Trautwein, C. & Tacke, F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front. Physiol. 3, 56 (2012).
11. Eckert, C., Klein, N., Kornek, M. & Lukacs-Kornek, V. The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. Front. Immunol. 6, 179 (2015).
12. Gao, B., Radaeva, S. & Park, O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 86, 513-528 (2009).
13. Tacke, F. & Zimmermann, H. W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60, 1090-1096 (2014).
14. Varol, C., Yona, S. & Jung, S. Origins and tissue-context-dependent fates of blood monocytes. Immunol. Cell Biol. 87, 30-38 (2009).
15. Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547-551 (2015).
16. Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91 (2013).
17. Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86-90 (2012).
18. Antoniades, C. G. et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology 56, 735-746 (2012).
19. Miller, J. C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888-899 (2012).
20. + DCs. J. Exp. Med. 206, 3115-3130 (2009).
21. Bamboat, Z. M. et al. Human liver dendritic cells promote T cell hyporesponsiveness. J. Immunol. 182, 1901-1911 (2009).
22. Heymann, F. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62, 279-291 (2015).
23. Helmy, K. Y. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006).
24. Knolle, P. et al. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22, 226-229 (1995).
25. Jenne, C. N. & Kubes, P. Immune surveillance by the liver. Nat. Immunol. 14, 996-1006 (2013).
26. low/neg accessory cells with dendritic-cell features. Blood 108, 218-227 (2006).
27. absent dendritic cells with tolerogenic potential. J. Immunol. 174, 4706-4717 (2005).
28. Wysocka, M., Montaner, L. J. & Karp, C. L. Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J. Immunol. 174, 7398-7402 (2005).
29. Kedarisetty, C. K. et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 148, 1362-1370.e7 (2015).
30. Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
31. Jurgens, B., Hainz, U., Fuchs, D., Felzmann, T. & Heitger, A. Interferon-γ-triggered indoleamine 2, 3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 114, 3235-3243 (2009).
32. Klugewitz, K., Adams, D. H., Emoto, M., Eulenburg, K. & Hamann, A. The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol. 25, 590-594 (2004).
33. Zimmermann, H. W. et al. Frequency and phenotype of human circulating and intrahepatic natural killer cell subsets is differentially regulated according to stage of chronic liver disease. Digestion 88, 1-16 (2013).
34. Tu, Z. et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205, 233-244 (2008).
35. Peng, H. & Tian, Z. Re-examining the origin and function of liver-resident NK cells. Trends Immunol. 36, 293-299 (2015).
36. Constantinides, M. G., McDonald, B. D., Verhoef, P. A. & Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397-401 (2014).
37. + NK cells. J. Immunol. 194, 2467-2471 (2015).
38. + NKT cells patrolling liver sinusoids. PLoS Biol. 3, e113 (2005).
39. Wehr, A. et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J. Immunol. 190, 5226-5236 (2013).
40. Trobonjaca, Z., Leithäuser, F., Möller, P., Schirmbeck, R. & Reimann, J. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-γ release by liver NKT cells. J. Immunol. 167, 1413-1422 (2001).
41. Schmieg, J., Yang, G., Franck, R. W., Van Rooijen, N. & Tsuji, M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl Acad. Sci. USA 102, 1127-1132 (2005).
42. Kenna, T. et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171, 1775-1779 (2003).
43. Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701-708 (2010).
44. Tang, X.-Z. et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J. Immunol. 190, 3142-3152 (2013).
45. von Oppen, N. et al. Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology 49, 1664-1672 (2009).
46. Tuncer, C., Oo, Y. H., Murphy, N., Adams, D. H. & Lalor, P. F. The regulation of T-cell recruitment to the human liver during acute liver failure. Liver Int. 33, 852-863 (2013).
47. Crispe, I. N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51-62 (2003).
48. Schildberg, F. A. et al. Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism. Hepatology 54, 262-272 (2011).
49. Winau, F. et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26, 117-129 (2007).
50. Weiskirchen, R. & Tacke, F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg. Nutr. 3, 344-363 (2014).
51. Charles, R. et al. Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation 96, 17-24 (2013).
52. You, Q., Cheng, L., Kedl, R. M. & Ju, C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 48, 978 (2008).
53. Yan, M. L., Wang, Y. D., Tian, Y. F., Lai, Z. D. & Yan, L. N. Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2, 3-dioxygenase. World J. Gastroenterol. 16, 636-640 (2010).
54. + T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology 116, 1428-1440 (1999).
55. Carambia, A. et al. Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J. Hepatol. 58, 112-118 (2013).
56. - regulatory T cells suppressing autoimmune hepatitis. Hepatology 50, 1904-1913 (2009).
57. + regulatory T cells by production of retinoic acid. J. Immunol. 190, 2009-2016 (2013).
58. Morita, M. et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am. J. Transplant. 10, 40-46 (2010).
59. + T cells results in antigen-specific T-cell tolerance. Nat. Med. 6, 1348-1354 (2000).
60. Limmer, A. et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur. J. Immunol. 35, 2970-2981 (2005).
61. + T cell tolerance. Hepatology 47, 296-305 (2008).
62. Holz, L. E. et al. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 135, 989-997 (2008).
63. Lopes, A. R. et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835-1845 (2008).
64. Benseler, V. et al. Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc. Natl Acad. Sci. USA 108, 16735-16740 (2011).
65. Chan, J. K. et al. Alarmins: awaiting a clinical response. J. Clin. Invest. 122, 2711-2719 (2012).
66. Arshad, M. I., Piquet-Pellorce, C. & Samson, M. IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int. 32, 1200-1210 (2012).
67. Schaap, F. G., Trauner, M. & Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11, 55-67 (2014).
68. Allen, K., Jaeschke, H. & Copple, B. L. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am. J. Pathol. 178, 175-186 (2011).
69. Bieghs, V. et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 144, 167-178.e1 (2013).
70. Teratani, T. et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142, 152-164.e10 (2012).
71. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 (2007).
72. Huebener, P. et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J. Clin. Invest. 125, 539-550 (2015).
73. Tsung, A. et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201, 1135-1143 (2005).
74. Krumm, B., Xiang, Y. & Deng, J. Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses. Protein Sci. 23, 526-538 (2014).
75. Volarevic, V. et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 56, 26-33 (2012).
76. McHedlidze, T. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357-371 (2013).
77. Erhardt, A. & Tiegs, G. IL-33 - A cytokine which balances on a knife's edge? J. Hepatol. 56, 7-10 (2012).
78. Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677-687 (2015).
79. Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
80. Kubes, P. & Mehal, W. Z. Sterile inflammation in the liver. Gastroenterology 143, 1158-1172 (2012).
81. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417-426 (2002).
82. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
83. Kamo, N. et al. ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology 58, 351-362 (2013).
84. Huang, H. et al. Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J. Immunol. 191, 2665-2679 (2013).
85. McDonald, B. et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366 (2010).
86. Amaral, S. S. et al. Altered responsiveness to extracellular ATP enhances acetaminophen hepatotoxicity. Cell Commun. Signal. 11, 10 (2013).
87. Wree, A. et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59, 898-910 (2014).
88. Toki, Y. et al. Extracellular ATP induces P2X7 receptor activation in mouse Kupffer cells, leading to release of IL-1β, HMGB1, and PGE2, decreased MHC class I expression and necrotic cell death. Biochem. Biophys. Res. Commun. 458, 771-776 (2015).
89. Hoque, R., Farooq, A., Ghani, A., Gorelick, F. & Mehal, W. Z. Lactate reduces liver and pancreatic injury in Toll-like receptor-and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity. Gastroenterology 146, 1763-1774 (2014).
90. Petrasek, J., Csak, T. & Szabo, G. Toll-like receptors in liver disease. Adv. Clin. Chem. 59, 155-201 (2013).
91. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59-64 (2014).
92. Mencin, A., Kluwe, J. & Schwabe, R. F. Toll-like receptors as targets in chronic liver diseases. Gut 58, 704 (2009).
93. + regulatory T cells. Hepatology 42, 193-199 (2005).
94. Paik, Y.-H. et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37, 1043-1055 (2003).
95. + T cell trapping in the liver. J. Immunol. 175, 1643-1650 (2005).
96. Nace, G. W. et al. Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology 58, 374-387 (2013).
97. Rivera, C. A. et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47, 571-579 (2007).
98. Inokuchi, S. et al. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol. Clin. Exp. Res. 35, 1509-1518 (2011).
99. Kesar, V. & Odin, J. A. Toll-like receptors and liver disease. Liver Int. 34, 184-196 (2014).
100. Funk, E., Kottilil, S., Gilliam, B. & Talwani, R. Tickling the TLR7 to cure viral hepatitis. J. Transl. Med. 12, 129 (2014).
101. Lanford, R. E. et al. GS-9620, an oral agonist of Tolllike receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144, 1508-1517.e10 (2013).
102. US National Library of Science. Safety and efficacy of GS-9620 for the treatment of chronic hepatitis B virus in virally-suppressed subjects. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02166047 (2014).
103. Imaeda, A. B. et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 119, 305-314 (2009).
104. Bamboat, Z. M. et al. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J. Clin. Invest. 120, 559-569 (2010).
105. Rensen, S. S. et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50, 1809-1817 (2009).
106. Segers, F. M. et al. Complement alternative pathway activation in human nonalcoholic steatohepatitis. PLoS ONE 9, e110053 (2014).
107. Shen, H., French, B. A., Liu, H., Tillman, B. C. & French, S. W. Increased activity of the complement system in the liver of patients with alcoholic hepatitis. Exp. Mol. Pathol. 97, 338-344 (2014).
108. Pritchard, M. T. et al. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 132, 1117-1126 (2007).
109. Bykov, I., Junnikkala, S., Pekna, M., Lindros, K. O. & Meri, S. Complement C3 contributes to ethanol-induced liver steatosis in mice. Ann. Med. 38, 280-286 (2006).
110. Cohen, J. I., Roychowdhury, S., McMullen, M. R., Stavitsky, A. B. & Nagy, L. E. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 139, 664-674.e1 (2010).
111. Xu, R., Huang, H., Zhang, Z. & Wang, F. S. The role of neutrophils in the development of liver diseases. Cell. Mol. Immunol. 11, 224-231 (2014).
112. Ramadori, G., Moriconi, F., Malik, I. & Dudas, J. Physiology and pathophysiology of liver inflammation, damage and repair. J. Physiol. Pharmacol. 59, S107-S117 (2008).
113. Marra, F. & Tacke, F. Roles for chemokines in liver disease. Gastroenterology 147, 577-594.e1 (2014).
114. Moles, A. et al. A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse. J. Hepatol. 60, 782 (2014).
115. Marques, P. E. et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology 56, 1971-1982 (2012).
116. Kolaczkowska, E. et al. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. Nat. Commun. 6, 6673 (2015).
117. McDonald, B., Urrutia, R., Yipp, B. G., Jenne, C. N. & Kubes, P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12, 324-333 (2012).
118. Jenne, C. N. et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 13, 169-180 (2013).
119. Jaeschke, H., Farhood, A. & Smith, C. W. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J. 4, 3355-3359 (1990).
120. Farhood, A. et al. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J. Leukoc. Biol. 57, 368-374 (1995).
121. Honda, M. et al. Intravital imaging of neutrophil recruitment in hepatic ischemia-reperfusion injury in mice. Transplantation 95, 551-558 (2013).
122. Jaeschke, H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol 27, 23-27 (2002).
123. Liang, W. et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1β-induced chronic inflammation. Lab. Invest. 94, 491-502 (2014).
124. O'Brien, K. M. et al. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am. J. Pathol. 183, 1498-1507 (2013).
125. Davies, L. C., Jenkins, S. J., Allen, J. E. & Taylor, P. R. Tissue-resident macrophages. Nat. Immunol. 14, 986 (2013).
126. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312-1326 (2014).
127. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008).
128. Hutchinson, J. A. et al. Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J. Immunol. 187, 2072-2078 (2011).
129. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288 (2014).
130. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
131. Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl Acad. Sci. USA 109, E3186-E3195 (2012).
132. + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50, 261-274 (2009).
133. + monocytes at a site of sterile injury. J. Exp. Med. 212, 447-456 (2015).
134. Zigmond, E. et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. J. Immunol. 193, 344-353 (2014).
135. Dragomir, A.-C. D., Sun, R., Choi, H., Laskin, J. D. & Laskin, D. L. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J. Immunol. 189, 5934-5941 (2012).
136. Krenkel, O., Mossanen, J. C. & Tacke, F. Immune mechanisms in acetaminophen-induced acute liver failure. Hepatobiliary Surg. Nutr. 3, 331-343 (2014).
137. Ju, C. et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol. 15, 1504-1513 (2002).
138. Stutchfield, B. M. et al. CSF1 restores innate immunity following liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.08.053 (2015).
139. Sun, Z. et al. Hepatic allograft-derived Kupffer cells regulate T cell response in rats. Liver Transpl. 9, 489-497 (2003).
140. Xie, X. et al. Kupffer cells promote acute rejection via induction of Th17 differentiation in rat liver allografts. Transplant. Proc. 42, 3784-3792 (2010).
141. Kim, H. Y., Kim, S. J. & Lee, S. M. Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion. FEBS J. 282, 259-270 (2015).
142. Ohkubo, H. et al. VEGFR1-positive macrophages facilitate liver repair and sinusoidal reconstruction after hepatic ischemia/reperfusion injury. PLoS ONE 9, e105533 (2014).
143. Ellett, J. D. et al. Murine Kupffer cells are protective in total hepatic ischemia/reperfusion injury with bowel congestion through IL-10. J. Immunol. 184, 5849-5858 (2010).
144. McNelis, J. C. & Olefsky, J. M. Macrophages, immunity, and metabolic disease. Immunity 41, 36-48 (2014).
145. Wan, J. et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59, 130-142 (2014).
146. Tomita, K. et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55, 415 (2006).
147. Leroux, A. et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol. 57, 141-149 (2012).
148. Csak, T. et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int. 34, 1402-1413 (2014).
149. Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 139, 323-334.e7 (2010).
150. Miura, K., Yang, L., van Rooijen, N., Ohnishi, H. & Seki, E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1310-G1321 (2012).
151. Baeck, C. et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426 (2012).
152. Boltjes, A., Movita, D., Boonstra, A. & Woltman, A. M. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J. Hepatol. 61, 660-671 (2014).
153. Movita, D. et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. J. Virol. 89, 4809-4817 (2015).
154. Gehring, A. J. et al. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J. Clin. Invest. 123, 3766-3776 (2013).
155. + T cells and successful immunotherapy against chronic viral liver infection. Nat. Immunol. 14, 574-583 (2013).
156. Tu, Z. et al. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology 138, 305-314 (2010).
157. Fletcher, N. F. et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 59, 1320-1330 (2014).
158. Negash, A. A. et al. IL-1 (3 production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9, e1003330 (2013).
159. Pallett, L. J. et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat. Med. 21, 591-600 (2015).
160. Hammerich, L. & Tacke, F Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World J. Gastrointest. Pathophysiol. 6, 43-50 (2015).
161. Hammerich, L. et al. Cyclic adenosine monophosphate-responsive element modulator alpha overexpression impairs function of hepatic myeloid-derived suppressor cells and aggravates immune-mediated hepatitis in mice. Hepatology 61, 990-1002 (2015).
162. Haverkamp, J. M. et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41, 947-959 (2014).
163. Zimmermann, H. W. et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 6, e21381 (2011).
164. Liaskou, E. et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 57, 385-398 (2013).
165. + monocytes across human liver sinusoidal endothelium. Hepatology 51, 2030-2039 (2010).
166. Zimmermann, H. W. et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS ONE 5, e11049 (2010).
167. Bernsmeier, C. et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 148, 603-615.e14 (2015).
168. Pradere, J.-P. et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58, 1461-1473 (2013).
169. Ehling, J. et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63, 1960-1971 (2014).
170. Heymann, F et al. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 55, 898-909 (2012).
171. 3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 52, 1769-1782 (2010).
172. Link, A. et al. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am. J. Pathol. 178, 1662-1675 (2011).
173. Tsung, A. et al. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J. Leukoc. Biol. 81, 119-128 (2007).
174. Henning, J. R. et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 58, 589-602 (2013).
175. Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880-886 (2010).
176. Yoneyama, H. et al. Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J. Exp. Med. 193, 35-49 (2001).
177. Connolly, M. K. et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-a. J. Clin. Invest. 119, 3213-3225 (2009).
178. Bosschaerts, T. et al. Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-y and MyD88 signaling. PLoS Pathog. 6, e1001045 (2010).
179. Jiao, J. et al. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology 55, 244-255 (2012).
180. Kahraman, A., Fingas, C. D., Syn, W. K., Gerken, G. & Canbay, A. Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 32, 370-382 (2012).
181. Wang, H., Feng, D., Park, O., Yin, S. & Gao, B. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-γ. Hepatology 58, 1474-1485 (2013).
182. Lynch, L. et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 37, 574-587 (2012).
183. Wondimu, Z., Santodomingo-Garzon, T., Le, T. & Swain, M. G. Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am. J. Pathol. 177, 2334-2346 (2010).
184. Wang, Y. et al. STAT4 knockout mice are more susceptible to concanavalin A-induced T-cell hepatitis. Am. J. Pathol. 184, 1785-1794 (2014).
185. Lee, K.-A. et al. Retinoic acid alleviates Con A-induced hepatitis and differentially regulates effector production in NKT cells. Eur. J. Immunol. 42, 1685-1694 (2012).
186. Santodomingo-Garzon, T., Han, J., Le, T., Yang, Y. & Swain, M. G. Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. Hepatology 49, 1267-1276 (2009).
187. Rehermann, B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat. Med. 19, 859-868 (2013).
188. High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 56, 1201-1213 (2012).
189. Eisenhardt, M. et al. The CXCR3+CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. PLoS ONE 7, e38846 (2012).
190. High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 56, 1201-1213 (2012).
191. Dunn, C. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667-680 (2007).
192. Peppa, D. et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 210, 99-114 (2013).
193. Zeissig, S. et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 18, 1060-1068 (2012).
194. Kenna, T. et al. CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver. Cancer Immunol. Immunother. 56, 563-572 (2007).
195. Schrumpf, E. et al. The biliary epithelium presents antigens to and activates natural killer T cells. Hepatology 62, 1249-1259 (2015).
196. Balmer, M. L. et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci. Transl. Med. 6, 237ra66 (2014).
197. Sertorio, M. et al. IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology 61, 1321-1331 (2015).
198. Kong, X. et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56, 1150-1159 (2012).
199. Gur, C. et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 61, 885-893 (2012).
200. Abu-Tair, L. et al. Natural killer cell-dependent anti-fibrotic pathway in liver injury via Toll-like receptor-9. PLoS ONE 8, e82571 (2013).
201. Park, O. et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49, 1683-1694 (2009).
202. Syn, W. K. et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51, 1998-2007 (2010).
203. + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549-564 (2014).
204. Gold, M. C. et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. 8, e1000407 (2010).
205. Le Bourhis, L. et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog. 9, e1003681 (2013).
206. Sawa, Y. et al. Hepatic interleukin-7 expression regulates T cell responses. Immunity 30, 447-457 (2009).
207. Jo, J. et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 10, e1004210 (2014).
208. Volpes, R., van den Oord, J. J. & Desmet, V. J. Memory T cells represent the predominant lymphocyte subset in acute and chronic liver inflammation. Hepatology 13, 826-829 (1991).
209. Bottcher, J. P. et al. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep. 3, 779-795 (2013).
210. Taubert, R. et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J. Hepatol. 61, 1106-1114 (2014).
211. Ferri, S. et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 52, 999-1007 (2010).
212. Hammerich, L. & Tacke, F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J. Gastrointest. Pathophysiol. 5, 107-113 (2014).
213. Heymann, F., Hamesch, K., Weiskirchen, R. & Tacke, F. The concanavalin A model of acute hepatitis in mice. Lab. Anim. 49, 12-20 (2015).
214. Tiegs, G., Hentschel, J. & Wendel, A. A. T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90, 196-203 (1992).
215. Burghardt, S. et al. Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. J. Immunol. 191, 5574-5582 (2013).
216. Hammerich, L. et al. Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59, 630-642 (2014).
217. Adams, D. H., Sanchez-Fueyo, A. & Samuel, D. From immunosuppression to tolerance. J. Hepatol. 62, S170-S185 (2015).
218. + T cells activated locally within the transplanted liver. J. Exp. Med. 203, 437-447 (2006).
219. Shen, X. et al. CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury. Hepatology 50, 1537-1546 (2009).
220. Rehermann, B. & Bertoletti, A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 61, 712-721 (2015).
221. + T cells by adeno-associated virus-transduced hepatocytes. Hepatology 52, 1068-1077 (2010).
222. + T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis. Am. J. Pathol. 179, 2370-2381 (2011).
223. Iannacone, M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1167-1169 (2005).
224. + T cells. Cell 161, 486-500 (2015).
225. + T cells from PD-1-mediated exhaustion. PLoS Pathog. 9, e1003490 (2013).
226. + T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J. Hepatol. 59, 427-433 (2013).
227. + T cell exhaustion in hepatitis B virus-induced immunotolerance. J. Immunol. 193, 1645-1653 (2014).
228. Tang, Y. et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 166, 281-290 (2011).
229. Sutti, S. et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 59, 886-897 (2014).
230. Chatzigeorgiou, A. et al. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology 60, 1196-1210 (2014).
231. Mucida, D. et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
232. Licata, L. A. et al. Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils. J. Leukoc. Biol. 94, 813-823 (2013).
233. Guillot, A. et al. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 59, 296-306 (2014).
234. Teixeira-Clerc, F. et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12, 671-676 (2006).
235. Mentink-Kane, M. M. et al. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13R α2. Gastroenterology 141, 2200-2209 (2011).
236. Markwick, L. J. L. et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 148, 590-602.e10 (2015).
237. Barron, L. & Wynn, T. A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G723-G728 (2011).
238. Tan, Z. et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J. Immunol. 191, 1835-1844 (2013).
239. Lin, Y. et al. Gut-derived lipopolysaccharide promotes T-cell-mediated hepatitis in mice through Toll-like receptor 4. Cancer Prev. Res. (Phila.) 5, 1090-1102 (2012).
240. Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765-776.e1-3 (2012).
241. Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181-194 (2014).
242. Affò, S. et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63, 1782-1792 (2014).
243. Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504-516 (2012).
244. Tacke, F. & Trautwein, C. Mechanisms of liver fibrosis resolution. J. Hepatol. 63, 1038-1039 (2015).
245. Mehal, W. Z., Iredale, J. & Friedman, S. L. Scraping fibrosis: expressway to the core of fibrosis. Nat. Med. 17, 552-553 (2011).
246. Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15-S24 (2015).
247. Mossanen, J. C. & Tacke, F. Role of lymphocytes in liver cancer. Oncoimmunology 2, e26468 (2013).
248. Kantari-Mimoun, C. et al. Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. Hepatology 61, 2042-2055 (2014).